Catalyst Pharmaceuticals Past Earnings Performance
Past criteria checks 6/6
Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 34.8% per year. Catalyst Pharmaceuticals's return on equity is 21.6%, and it has net margins of 31%.
Key information
19.0%
Earnings growth rate
17.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 34.8% |
| Return on equity | 21.6% |
| Net Margin | 31.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve
Nov 13
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings
Nov 07Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jul 24Catalyst Pharmaceuticals: New Products In Proving Phase
Jul 06Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11Revenue & Expenses Breakdown
How Catalyst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 460 | 143 | 176 | 0 |
| 30 Jun 24 | 434 | 68 | 163 | 0 |
| 31 Mar 24 | 411 | 65 | 151 | 0 |
| 31 Dec 23 | 398 | 71 | 134 | 0 |
| 30 Sep 23 | 348 | 62 | 106 | 0 |
| 30 Jun 23 | 303 | 116 | 86 | 0 |
| 31 Mar 23 | 256 | 99 | 70 | 0 |
| 31 Dec 22 | 214 | 83 | 57 | 0 |
| 30 Sep 22 | 192 | 67 | 56 | 0 |
| 30 Jun 22 | 170 | 54 | 55 | 0 |
| 31 Mar 22 | 154 | 45 | 53 | 0 |
| 31 Dec 21 | 141 | 39 | 50 | 0 |
| 30 Sep 21 | 134 | 42 | 50 | 0 |
| 30 Jun 21 | 127 | 75 | 48 | 0 |
| 31 Mar 21 | 120 | 72 | 47 | 0 |
| 31 Dec 20 | 119 | 75 | 44 | 0 |
| 30 Sep 20 | 118 | 71 | 42 | 0 |
| 30 Jun 20 | 120 | 42 | 40 | 0 |
| 31 Mar 20 | 119 | 43 | 39 | 0 |
| 31 Dec 19 | 102 | 32 | 37 | 0 |
| 30 Sep 19 | 73 | 9 | 32 | 0 |
| 30 Jun 19 | 42 | -12 | 28 | 0 |
| 31 Mar 19 | 13 | -29 | 22 | 0 |
| 31 Dec 18 | 1 | -34 | 16 | 0 |
| 30 Sep 18 | 0 | -25 | 11 | 0 |
| 30 Jun 18 | 0 | -21 | 9 | 0 |
| 31 Mar 18 | 0 | -19 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 7 | 0 |
| 30 Sep 17 | 0 | -17 | 6 | 0 |
| 30 Jun 17 | 0 | -17 | 6 | 0 |
| 31 Mar 17 | 0 | -18 | 6 | -4 |
| 31 Dec 16 | 0 | -18 | 7 | 0 |
| 30 Sep 16 | 0 | -20 | 9 | 4 |
| 30 Jun 16 | 0 | -20 | 9 | 7 |
| 31 Mar 16 | 0 | -20 | 9 | 13 |
| 31 Dec 15 | 0 | -20 | 9 | 0 |
| 30 Sep 15 | 0 | -18 | 8 | 10 |
| 30 Jun 15 | 0 | -18 | 7 | 10 |
| 31 Mar 15 | 0 | -17 | 6 | 10 |
| 31 Dec 14 | 0 | -16 | 4 | 10 |
| 30 Sep 14 | 0 | -13 | 4 | 10 |
| 30 Jun 14 | 0 | -14 | 3 | 10 |
| 31 Mar 14 | 0 | -14 | 2 | 10 |
Quality Earnings: CPRX has high quality earnings.
Growing Profit Margin: CPRX's current net profit margins (31%) are higher than last year (17.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPRX's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: CPRX's earnings growth over the past year (130.2%) exceeds its 5-year average (19% per year).
Earnings vs Industry: CPRX earnings growth over the past year (130.2%) exceeded the Biotechs industry 16.6%.
Return on Equity
High ROE: CPRX's Return on Equity (21.6%) is considered high.